ArticleJournal for immunotherapy of cancer2022

Extensive plasma proteomic profiling revealed receptor activator of nuclear factor kappa-Β ligand (RANKL) as emerging biomarker of nivolumab clinical benefit in patients with metastatic renal cell carcinoma.

Sonia Simonetti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.